List of Implants Companies in Minnesota - 17

4C Medical Technologies, Inc. is a medical device company developing a novel minimally invasive solution for the treatment of mitral regurgitation (MR). We are the first transcatheter MR therapy that directly addresses mitral regurgitation without replacing the native mitral valve, thus preserving the native mitral annulus and left ventricle. The device is positioned supra annular to the leaking native mitral valve to stop the leak from entering the left atrium. Its atrial only fixation ensures minimal disruption to critical cardiac structures within the left ventricle including the chordae tendineae and the left ventricular outflow tract. Our initial focus is to develop a novel therapy for mitral regurgitation (MR), and subsequently for tricuspid regurgitation (TR).

Cardiovascular Systems, Inc. (CSI) is committed to providing innovative solutions for the revascularization of patients with complex coronary and peripheral artery disease (PAD). Our primary focus is helping physicians conquer even the most difficult disease states, including the challenge of arterial calcium for the millions who suffer from PAD and Complex PCI. CSI is committed to clinical rigor, constant innovation, and a defining drive to set the standard in safe, effective, economical medical devices that improve patient outcomes. We are equally committed to creating an invigorating work environment for people who align with our Core Values of accountability, integrity, excellence, courage, velocity, and community. When each of our employees lives our Core Values, we're doing everything we can to achieve our mission: Saving Limbs. Saving Lives. Every Day. It is the policy of CSI to provide equal employment opportunity (EEO) to all persons regardless of age, color, national origin, citizenship status, physical or mental disability, race, religion, creed, gender, sex, sexual orientation, gender identity and/or expression, genetic information, marital status, status with regard to public assistance, veteran status, or any other characteristic protected by federal, state or local law. In addition, CSI will provide reasonable accommodations for qualified individuals with disabilities. For more information, visit www.CSI360.com or connect with us on Twitter and Facebook. Read important safety information (https://csi360.com/indications-statements-important-safety-and-risk-information/).

CoraVie Medical's implantable, continuous blood pressure monitor informs treatment decisions to improve lives. The end to end solution improves patient compliance to monitoring and improves blood pressure reliability and actionability. By monitoring trends over day and night, CoraVie enables timely notification of changing health status.

Cryosa is a clinical stage company developing a treatment for moderate to severe Obstructive Sleep Apnea (OSA). We believe that mask-free, hose-free, implant-free treatment is possible. Everyone is free to sleep, free to rest and free to live brighter days.

CVRx is a commercial stage, public (NASDAQ: CVRX) medical devices company located in Minneapolis, Minnesota. The company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. Barostim™ triggers carotid baroreceptors - the body's own natural blood flow regulation system - which signals the brain to regulate cardiovascular function. Patient Stories on CVRx: The accounts and quotes of patients are genuine and documented. These stories represent a unique individual experience and does not provide any indication, guide, warranty or guarantee as to the response other people may have to CVRx technologies. Barostim is a prescriptive device. For a list of all potential benefits and risks go to www.cvrx.com/benefit-risk-analysis/

Envoy Medical (Nasdaq: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.

For ordering information, please contact: 3M+KCI at +1-800-275-4524, KCI Express® https://mykci.com/kci-express, or Your local 3M+KCI Sales representative ________________________ Managing ostomy complications and intestinal fistulas is a challenge. A high output ostomy stoma or enteric fistula can produce two to seven liters of effluent per day which can cause edema, wound formation, complications and infections. To improve the management of patients with enteric fistulas and high output ostomy stomas we developed the Wound Crown®, Fistula Funnel® and Isolator Strip®. These barrier devices have been used effectively to compress the surface of the body around enterocutaneous fistulas, enteroatmospheric fistulas, ostomy stomas, and wound drains with moderate to high output levels to seal and protect the perimeter skin from effluent and reduce edema.

Medtronic plc is an Irish medical device company. The company's operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Dublin, Ireland. Medtronic operates in more than 140 countries and employs over 90,000 people worldwide. The company is the world's largest standalone medical technology development company.

Melodi Health offers novel technologies that improve patient outcomes for women undergoing breast surgery. Melodi Health manufactures the Melodi Matrix, designed to support the soft tissue space around a prosthetic device while delivering antibiotics to the surrounding tissue. The Melodi Matrix is currently an investigational device being studied in a prospective, multi-center, randomized, controlled clinical trial in breast reconstruction.

Since 1996, Minnetronix Medical has accelerated medical device breakthroughs as a design, development and manufacturing partner to leading device companies around the world. Today, through life-cycle efficiency, opportunity realization, and increased utility, the organization is creating value in key technology segments, including RF energy, fluid and gas management, optical systems, and stimulation and active wearables. From design and manufacturing services to whole product solutions, Minnetronix brings expansive industry insight and intentional technical acumen, delivering better medical devices to market, faster. Minnetronix is based in St. Paul, Minnesota. ​

What we know: - Currently, 106,000 people in the U.S. are on the waitlist for a life-saving organ transplant. - 60% of patients on the waitlist will not receive the organ they need. - 17 people in the U.S. die each day due to the lack of available organs. What we're doing: Miromatrix Medical was founded with the mission to eliminate the transplant waitlist. Headquartered in Eden Prairie, Minnesota, we bioengineer organs through our patented perfusion decellularization and recellularization technology. We take what nature designed -- a fully functioning liver or kidney -- and with our patented technology, remove all of the cells from discarded pig organs. What's left is a ‘scaffold'; all of the organ's natural design and architecture remains. Then, from the inside out, we seed new, living human cells back into the organ -- ultimately creating completely functional, transplantable organs with the potential to save thousands of lives every year.

Peytant Solutions, Inc. (PSI) is a medical device company, incorporating Regenerative Human Biomaterial   with  absorbable and alloy implant technologies. Our percutaneous, biologic AmnioStent...

The number of patients requiring hemodialysis is expected to reach 774,000 with an annual incidence of more than 160,000 new patients per year who require vascular access for hemodialysis. Vascular access for hemodialysis is creating a special pathway in the body to cleanse the blood when the kidneys aren't working (End Stage Renal Disease). Two methods of permanent vascular access: Arteriovenous Fistula (AVF) Arteriovenous Grafts (AVG) Phraxis, Inc is a Minneapolis MN based company that has developed the EndoForce™ Venous Anastomotic Connector to provide a procedural technique for AVG implantation that may lessen the neointimal hyperplasia-induced stenosis that is associated with conventional sutured venous anastomosis. See our complete clinical study of the EndoForce™ Venous Endovascular Anastomotic Connector here: https://pubmed.ncbi.nlm.nih.gov/36895157/ And join the movement at www.phraxis.com as we seek FDA approval. The EndoForce™ Venous Anastomotic Connector is an investigational device. Limited by Federal (United States) law to investigational use.

Ponte Biosciences, Inc. is a preclinical biotherapeutic company focused on developing a cell-based bioartificial liver system to treat acute forms of liver failure. The Company's Spheroid Reservoir Bioartificial Liver (SRBAL) system was developed at the Mayo Clinic and utilizes metabolically active primary hepatocytes (liver cells) to replace and/or supplement liver function for patients with liver failure being treated in the Intensive Care Unit (ICU).

ShiraTronics is a forward-thinking medtech startup committed to revolutionizing the field of migraine medicine with our minimally invasive neuromodulation system. Our mission? To transform the lives of those facing Chronic Migraine by reducing headache days and restoring quality of life.

Spineology's OptiMesh is the only conforming, patient specific lumbar expandable implant on the market. OptiMesh is delivered through the smallest insertion profile, dynamically conforms to a patient’s unique endplate morphology, and powerfully expands to one of the largest implant footprints available. Spineology’s OptiMesh features our unique Conform and Expand™ technology, enabling a custom anatomical fit for lumbar fusion surgical patients. OptiMesh is designed to overcome the challenges of static and mechanically expandable implants.

GOAL: DISPRUPT AND TAKE OVER AN OLD AND OVERLOOKED $150 MILLION/YR. MARKET BY LEVERAGING OUR SUPERIOR AND CLINICALLY PROVEN DEVICE DESIGN WHY IS IT POSSIBLE? Current oral airways have been continually proven to be defective and studies have proven that these common airways are not adequate to maintain the oropharynx airway. Further, they are not designed to control the ever-problematic tongue. Even more, our studies showed that current oral airways possess no proportional dimensional standards in relation to how it would impact the oropharyngeal area. THE PROBLEM The biggest impediment, after placement of an oral airway, is the relaxation of the soft tissue structures in the hypopharynx. These structures are inclined to collapse, thus obstructing airflow, while occurring from both front-to-back and side-to-side, thus greatly decreasing the size of the oral opening. In relation, literally every patient before and after anesthesia, CPR, or sedation, is provided with a manual jaw-thrust to prevent the tongue from falling back and obstructing the airway. Furthermore, almost every patient intubated is provided with an airway to prevent biting of the soft endotracheal tube. Both of these procedures involve manually protracting the lower jaw by pulling it forward relative to the upper jaw. SOLUTION Studies have proven that mandibular advancement increases the oropharynx opening under anesthesia, but nobody designed that embodiment into an oral airway, or thought to design an airway to also control the tongue…until now. INTRODUCING OUR LOWER-JAW THRUST (LJT) ORAL AIRWAYS WHICH ARE ENGINEERED TO INCREASE THE OPENING OF THE OROPHARYNX AIRWAY & CONTROL THE TONGUE